4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
7.810 USD   +5.97%
05/13SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps Outperform Rating
MT
05/124D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/124D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics : Evercore ISI Starts 4D Molecular Therapeutics at Outperform With $70 Price Target

01/05/2021 | 08:29am EDT


© MT Newswires 2021
All news about 4D MOLECULAR THERAPEUTICS, INC.
05/13SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps O..
MT
05/124D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condi..
AQ
05/124D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended Ma..
CI
05/12Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Posts Q1 Revenue $1.2M
MT
05/124D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Cor..
GL
05/124D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Cor..
AQ
05/10TRANSCRIPT : 4D Molecular Therapeutics, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/054D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Confere..
GL
05/054D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Confere..
AQ
04/044D Molecular Therapeutics Starts Cystic Fibrosis Trial with Dosing of First Patient
MT
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 15,0 M - -
Net income 2022 -84,7 M - -
Net cash 2022 47,1 M - -
P/E ratio 2022 -2,59x
Yield 2022 -
Capitalization 252 M 252 M -
EV / Sales 2022 13,7x
EV / Sales 2023 18,5x
Nbr of Employees 137
Free-Float 88,3%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,81 $
Average target price 28,25 $
Spread / Average Target 262%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-64.40%252
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567